ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2716

Does Secretory Immunoglobulin a Influence Disease Activity in Patients with Reactive Arthritis and Undifferentiated Spondylarthritis?

fabian Alexander salas-Cuestas1, Consuelo Romero Sanchez2,3, WILSON BAUTISTA-MOLANO4, Juan Manuel Bello-Gualtero5,6, Ivonne Arias C7, Daniel Herrera8 and Rafael Valle-Oñate6,9, 1School of Medicine, Universidad Militar Nueva Granada, Bogotá, Colombia, Bogota DC, Colombia, 2Rheumatology, School of Medicine HMC / UMNG, Bogota, Colombia, 3Rheumatology and Immunology, Hospital Militar Central, Bogota DC, Colombia, 4Rheumatology Department, School of Medicine, UMNG / HMC, Bogotá, Colombia, 5Faculty of Medicine, Universidad Militar Nueva Granada, Bogotá, Colombia, 6Rheumatology and Immunology Department,Hospital Militar Central, Bogota, Colombia, 73. Instituto de Genética Humana, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia., Bogota DC, Colombia, 8Genetic, Instituto de Genética Humana, Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia, 9School of Medicine, Universidad Militar Nueva Granada, Bogota, Colombia

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Spondylarthropathy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Spondylarthropathies (SpA) comprise a group of rheumatic diseases such as ankylosing spondylitis (AS), arthritis/spondylitis with inflammatory bowel disease, arthritis/spondylitis with psoriasis (PsA), reactive arthritis (ReA) and undifferentiated spondyloarthritis (uSpA). Their genetic background, familial aggregation, pathophysiology and overlapping clinical manifestations suggest a common origin between them. Previous trials have suggested the role of the intestinal mucosa in the etiopathogenesis of SpA. Increased serum levels of IgA and secretory IgA (SIgA) in AS patients have also been reported, but whether SIgA has a role in the pathogenesis of ReA and uSpA remains unknown.

Methods:  Cross sectional study. Serum concentrations of SIgA and total IgA were measured using ELISA and nephelometry in patients and healthy subjects. Activity indices (BASDI, Ankylosing Spondylitis Disease Activity Score (ASDAS)) were applied in each patient. Statistical analysis was performed using Stata 11.2® software for Windows. t Student test was used to compare different groups or subgroups. Pearson correlation was used to measure the correlation degree between SIgA, IgA and disease activity. Multiple linear regression models were used to evaluate the strength of the association. The study was approved by the hospital’s ethics committee.

Results:  46 patients (78,2% men, mean age 34,8±12,3y) and 53 controls (41% men, mean age 32y) were included. The mean serum levels of SIgA were higher in patients (19,85±9,97 µg/ml) than in healthy subjects (10,82 ±6,5 µg/ml p <0.000). Mean total IgA levels did not show statistical differences between patients and healthy subjects (275±123 mg/dl vs 284,33±107 p=0,72). SIgA levels correlated with disease activity in patients using the following activity index: BASDI (r= -0.42, p=0.0046), ASDAS-CRP (r= -0.37, p=0.014) and ASDAS-ESR (r= -0.45, p=0.0021). Negative correlation between SIgA and all activity index was higher in HLA-B27+ patients (BASDI r= -0.70, p=0.0009, ASDAS-CRP r= -0.58, p=0.0093 and ASDAS-ESR r= -0.57, p=0.0083) than in HLA-B27– patients. Multivariate regression models showed linear association between SIgA and BASDI (-0,12 p=0,005), ASDAS-CRP (-0,04 p=0,014) and ASDAS-ESR (-0,048 p=0,002). Table 1.

Conclusion:  High serum levels of SIgA were associated with decreased activity in patients with ReA and uSpA. SigA is a very important molecule participating in host defense of intestinal mucosa, playing an important role in homeostasis. These findings highlight the importance of the development of new studies to reach a better understanding of the role of the intestinal mucosa in the different SpA phenotypes.


Disclosure: F. A. salas-Cuestas, None; C. Romero Sanchez, None; W. BAUTISTA-MOLANO, None; J. M. Bello-Gualtero, None; I. Arias C, None; D. Herrera, None; R. Valle-Oñate, None.

To cite this abstract in AMA style:

salas-Cuestas FA, Romero Sanchez C, BAUTISTA-MOLANO W, Bello-Gualtero JM, Arias C I, Herrera D, Valle-Oñate R. Does Secretory Immunoglobulin a Influence Disease Activity in Patients with Reactive Arthritis and Undifferentiated Spondylarthritis? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/does-secretory-immunoglobulin-a-influence-disease-activity-in-patients-with-reactive-arthritis-and-undifferentiated-spondylarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-secretory-immunoglobulin-a-influence-disease-activity-in-patients-with-reactive-arthritis-and-undifferentiated-spondylarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology